Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

CoAxia gets $21.5mm through its Series D round

24 Sep 2020

Executive Summary

First-time backer Sofinnova Partners has led CoAxia's (ischemia devices) $21.5mm oversubscribed Series D venture round and will contribute a board member. All prior major investors--Affinity Capital Management, Baird Venture Partners, Canaan Venture Partners, Johnson & Johnson Development Corp., and Prism Ventureworks--participated. CoAxia will use the funds to finish its pivotal trial of NeuroFlo for acute ischemic stroke and to investigate the product in combination with other devices and drugs.

Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By